Short title: Bilirubin and type 2 diabetes 22 Word count of the abstract: 205 words 23 Word count of the manuscript: 4, 179 words
INTRODUCTION
In this formula, OR genotupe-T2D is the OR resulting from logistic regression between rs6742078 156 and T2D, representing risk of T2D per each copy of the rs6742078(T) allele (model C). The 157 ß genotype-bilirubin coefficient is obtained from the regression of bilirubin on the SNP per each 158 copy of the T allele of rs6742078 (model B). To validate the causal estimate derived from the 159 Wald-type method, we used two alternative methods, called the two-stage least squares 160 (2SLS) method and the multiplicative generalized method of moments (MGMM) ( Table 3) . 161 The first stage of the 2SLS method is to examine the observational association between (14) . To obtain the MGMM β IV , the Stata command "ivpois" was used (24). 166 The MGMM does not require distributional assumptions about bilirubin and thus can provide 167 consistent estimation of causal OR (24). 168 To examine whether the association between bilirubin and T2D has 'endogeneity', we 169 compared the IV estimate with the observed estimate from standard logistic regression 170 analysis (i.e., β bilirubin-T2D coefficient) using the Durbin-Wu-Hausman (DWH) chi-square test, 171 which assesses whether there is a difference between these two estimates (14; 24). We 172 calculated the power of our study to detect a causal effect for bilirubin, given our sample size 173 and bilirubin variation explained by rs6742078 (17; 25). 174 To account for potential confounding bias, we tested whether rs6742078 is associated 175 with common diabetes risk factors, other variables (Table 2) To test for pleiotropy, we performed logistic regression with bilirubin as independent 179 variable and T2D as dependent variable and saved the residuals. Next, we tested the 180 Page 9 of 40 Diabetes correlation between the genotype and the residuals that are independent of total bilirubin 181 levels (26). To further dissect potential pleiotropy, we also calculated IV estimates from two 182 additional bilirubin SNPs, namely rs4149056 in SLCO1B1 and rs16928809 in SLC22A18(17), 183 in PREVEND. Additionally, we extracted effect estimates for rs6742078, rs4149056 and 184 rs16928809 from publically-available GWAS data on bilirubin, T2D (DIAGRAM) or 185 glycemic traits (MAGIC) (27-29) ( Supplementary Table 2 ), and we calculated a summary 186 statistics genetic risk score for bilirubin, like described previously (27) . We then evaluated 187 the presence of heterogeneity (derived from the likelihood-based method (27)) on causal 188 effects of these three SNPs on T2D, glucose, insulin and HOMA-IR (27; 29) ( Table 3 ). The 189 presence of heterogeneity indicates potential pleiotropy (30). 190 We also performed a series of secondary analyses. Firstly, we repeated regression 191 models for bilirubin levels and rs6742078 by using a weighted method to compensate for the 192 enrichment of the PREVEND cohort with microalbuminuric individuals (18 Association between rs6742078 and T2D. We observed that one copy increase in number of 237 the rs6742078*T allele was associated with T2D risk with an OR of 0.69 (95%CI, 0.54-0.90; 238 P=0.006), which corresponds to a 31% decreased risk of T2D ( Figure 3 , the right panel).
239
Adjustment for bilirubin attenuated the association between rs6742078 and T2D risk (OR in log-transformed bilirubin levels. We observed that direction of the IV and observed 251 estimates were similar with a slightly larger effect size for the IV estimate (P endogeneity =0.19).
252
The use of two alternative methods for IV estimation provided evidence of causal effect, 253 which was also comparable to the observed OR for T2D (P endogeneity =0.18 or 0.22; Table 3 ).
255
Confounding and pleiotropy 256 We found no evidence that rs6742078 is associated with potential confounders like various 257 demographic, lifestyle and clinical variables (Table 2) . Thus, we assumed that the association between the IV and T2D was mainly free of confounding. To test for pleiotropy, we assessed 259 the correlation between rs6742078 and the residuals from the logistic regression for T2D (as 260 dependent variable) and bilirubin (as independent variable). There was no evidence for 261 pleiotropy (P for correlation =0.11). We consistently observed no heterogeneity for the causal 262 effects of bilirubin on T2D risk or glycemic traits when we used a summary statistics genetic 263 score including rs6742078, rs4149056 and rs16928809 ( Table 3 ). Details of the association of 264 individual SNPs with bilirubin, T2D and glycemic traits are given in Supplementary Table 2 . 265 In PREVEND, while rs6742078 explained 19.5% of bilirubin variation, rs4149056 and 266 rs16928809 only explained 0.18% and 0.15% of the variance, respectively. This limits use of 267 these SNPs as a single IV. For rs4149056 and rs16928809, we estimated causal ORs of 0.58 268 (0.05-6.08) and 0.17 (0.02-2.16) in PREVEND. These estimates lack power for detection of 269 associations as these two SNPs explained only a very small amount of bilirubin variation and 270 therefore are to be considered weak IVs.
272
Secondary analyses 273 In subsequent analyses, we repeated the analyses in models A and C, when weighted for 274 individuals with a mean urine albumin >10 mg/L. The results of these complex design 275 analyses were similar to that of the main analyses, with an OR of 0.79 (95%CI, 0.66-0.95; 276 P=0.01) per 1-SD increase in log-transformed bilirubin, and an OR of 0.59 (95%CI, 0.47-277 0.97; P<0.001) for the rs6742078*T allele. Secondly, we found no evidence for interactions 278 of sex and age with bilirubin and rs6742078 (P for sex-interaction =0.49 and P for age-interaction =0.38 279 with bilirubin; P for sex-interaction =0.96 and P for age-interaction =0.25 with rs6742078) for the risk of we observed no evidence of an association between the drop-out rates (82.9% and 71.3% of 286 participants who underwent the second and the third round, respectively) and the genotype 287 (P for correlation =0.15). Sixthly, we found an OR of 0.93 (95%CI, 0.69-1.26) per each T allele of 288 rs6742078 for prevalent T2D; and when we performed a combined analysis of both prevalent 289 and incident T2D, our findings remained materially unchanged (OR 0.77 [95%CI, 0.64-290 0.93]). In further analysis, we tested for another UGT1A1 SNP, rs887829 (in perfect LD with 291 rs6742978; r 2 =1.0), which has been shown to be strongly associated with bilirubin levels in 292 GWAS data (31). In our cohort, the rs887829*T-allele was associated with decreased risk of 293 T2D (OR 0.70 [95% CI, 0.54-0.89]), which was comparable to that of the rs6742978*T-294 allele. Finally, we observed no evidence of systematic differences between the participants 295 who were included in main analysis compared with the rest of cohort participants without 296 diabetes at baseline (data not shown). In this prospective cohort study, we investigated whether we could provide evidence that 300 bilirubin is causally associated with risk of new-onset T2D. We demonstrated the rs6742078* 301 T in the UGT1A1 locus is strongly associated with elevated levels of endogenous bilirubin 302 and is also associated with new-onset T2D. Several studies have previously demonstrated 303 associations between bilirubin and T2D in animal models and in humans (1) (2) (3) (4) (5) (6) powerful, but still present was the association with rs4149056, a functional SNP of the 325 SLCO1B1 locus, which accounted for 0.6% of bilirubin variation (17). In our cohort study, 326 we observed that 19.5% of bilirubin variation was explained by the UGT1A1 rs6742078 SNP. 327 It is likely that the association of rs6742078 with bilirubin can be explained for a large 328 proportion by the functional UGT1A1*28 genetic variant, which has been found to be in high 329 LD (r 2 =0.88) with rs6742078 (17). Therefore, the contribution of genetic variation in 330 UGT1A1 to risk of T2D could be greater than estimated from associations observed for 331 rs6742078. The genetically determined component of protective effects may also vary 332 globally as the TA repeat in the UGT1A1 promoter has other, less common functional 333 variants, e.g., the UGT1A1*6 variant, which is more often observed in Asians with Japanese 334 or Chinese ancestry (45).
335
From phenotypic perspective, the Framingham heart study has found that the 336 UGT1A1*28 variant was associated with both bilirubin and cardiovascular disease (CVD) (5).
337
However, the relationships of the UGT1A1 SNPs with CVD, glycemic traits and diabetes 338 have been inconsistent, possibly due to differences in design and populations across studies 339 (23). In the present study, we found that the rs6742078 SNP was associated with T2D risk. 340 We tested whether rs6742078 was associated to glycemic traits that were recently evaluated 341 in meta-analysis of 21 GWA studies (29). rs6742078 was associated with fasting glucose (β=- 
363
In our study, we used a strong IV, rs6742078, which satisfied requirements for 364 Mendelian randomization (48), to examine potential causal relationship between bilirubin and 365 T2D in a large population-based study. Using this approach, we directly investigated a 366 relationship between genotype and phenotype independent of potential confounders. Other 367 bilirubin SNPs, rs4149056 and rs16928809 (17), may not be selected as a single IV, given the 368 fact that the strength of these instruments is limited (25) because of the small amount of 369 bilirubin variation that is explained by these two SNPs (0.18% and 0.15% in PREVEND, 370 respectively).
371
Our findings may have implications for prevention or prediction of T2D and its 372 complications. For example, Gilbert syndrome which is characterized by moderate 373 Page 18 of 40 Diabetes hyperbilirubinemia exists in 5-10% of the general population (5; 16; 49). It has been shown 374 that diabetic patients with Gilbert syndrome have reduced markers of oxidative stress and 375 decreased risk of diabetic nephropathy and CVD (5; 49). One may speculate that modulation 376 of bilirubin levels (e.g., using medical interventions that inhibit UGT1A1) might have 377 protective effects against the risk of T2D (45). A search for the sources of increase in 378 bilirubin levels or its antioxidative capacity (e.g., effective therapeutics with minimal adverse 379 effects) merits further investigations. 380 One major concern remaining in the context of Mendelian randomization, is that we 381 cannot completely control for the possibility of reverse causality, unobserved confounding 382 and pleiotropy (14; 50). The functional UGT1A1*28 variant (in high LD with rs6742078) 383 which is associated with a 10-35% reduction in UGT1A1 activity is mainly involved in 384 glucuronidation of bilirubin, but also other compounds (e.g., estrogen), and drugs (e.g., 385 irinotecan) (45; 51). Yet, the effects of the genotype on phenotypic traits other than bilirubin 386 and their consequences on disease outcomes (e.g., cancer) remain inconclusive. An extensive 387 knowledge of gene function and the associated biological processes is needed to better 388 understand to what extend such genetic variation in the human genome contributes to lifelong 389 protection against T2D. Our cohort is predominantly comprised of white adults of Dutch 390 descent, and it is therefore unknown whether the findings of our study can be generalized to 391 other populations (18). The PREVEND cohort was enriched for individuals with 392 microalbuminuria at baseline. However, in a secondary analysis, we used a weighted method 393 to compensate this, and this did not affect our results.
394
In summary, endogenous bilirubin and the most highly associated SNP, rs6742078 in 395 the UGT1A1 locus, are associated with risk of T2D. We observed consistent effect estimates The bilirubin genetic risk score consisted of rs6742078 plus two other bilirubin SNPs in SLCO1B1, rs4149056 and in SLC22A18, rs16928809 (17; 27; 29). *The causal ORs for T2D were estimated using the Wald type method, the two-stage least squares (2SLS) method, the multiplicative generalized method of moments (MGMM) and the summary statistics (27; 28). The causal OR for T2D was calculated as OR=exp(β IV ). †The DIAGRAM GWAS includes both prevalent and incident cases of type 2 diabetes. ‡The causal β coefficient (95%CI) for glucose (mmol/L), insulin and HOMA-IR was estimated for each SNP separately and the genetic risk score which is based on the combination of these three SNPs.
Page 31 of 40 Diabetes Figure 1 : Study population sample from the PREVEND study cohort. For quality control (QC), samples were excluded (n=367) due to call rates below 0.95, sex mismatch, duplicate discordance, contamination and genetic similarity (identity by state > 0.2). Population stratification was assessed by principal component analysis over the sample correlation matrix, based on 16,842 independent (LD-pruned) SNPs. We excluded samples when they diverged from the mean with at least 3 standard deviations (Z-score > 3) for the first five principal components. 
